MAP2K7 and colonic neoplasm: A similar effect on ERKs activation was observed upon exposure to ruxolitinib, supporting the hypothesis that colon cancer cells became sensitized to JAK inhibitors when they are treated with inhibitors of MEK-ERK pathway [25] (Additional file 3: Figure S6b).